Jeffrey S. Glenn - 11 Mar 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role: Director
Signature: /s/ Sriram Ryali, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 11 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 11 Mar 2022, 20:06:40 UTC
Next filing: 27 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EIGR	Common Stock	Award	$0	+6,000	+7.9%	$0.000000	82,355	11 Mar 2022	Direct	F1
holding	EIGR	Common Stock						5,000	11 Mar 2022	By spouse
holding	EIGR	Common Stock						460	11 Mar 2022	By son
holding	EIGR	Common Stock						151,064	11 Mar 2022	By Eiger Group International, Inc.	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EIGR	Stock Option (Right to Buy)	Award	$0	+12,000		$0.000000	12,000	11 Mar 2022	Common Stock	12,000	$5.10	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 11, 2022.
F2	Shares are held by Eiger Group International, Inc. ("EGI"). The Reporting Person is the Chief Executive Officer of EGI and has sole power to vote and sole power to dispose of shares directly owned by EGI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F3	The option vests in equal monthly installments over 12 months measured from March 11, 2022 subject to Reporting Person's continuous service status as of each such date.